Human Health
August 2010
20/08/10
Additional Phase III Clinical Trial with UrocidinTM Expected to Commence in 2010
February 2010
12/02/10
Bioniche Achieves Two Additional Milestones Under Licensing Agreement; Endo Takes up Global Rights
November 2009
25/11/09
Bioniche Strengthens the International Patent Portfolio for its MCC Technology Platform
August 2009
24/08/09
Bioniche Phase III Clinical Trial with Urocidin™ Given Continued Green Light by DMC
July 2009
10/07/09
Bioniche Life Sciences Inc. and Endo Pharmaceuticals Inc. Sign Licensing Agreement for UrocidinTM
May 2009
22/05/09
Bioniche Phase III Clinical Trial with Urocidin™ Progressing Well
March 2009
31/03/09
Bioniche Completes Recruitment in First Phase III Clinical Trial with UrocidinTM
February 2009
18/02/09
Bioniche Phase II Bladder Cancer Trial Results Published in The Journal of Urology
November 2008
24/11/08
Bioniche Presents MCC Data at the SIU World Uro-Oncology Update in Santiago, Chile
17/11/08
Update on Bioniche Phase III Clinical Trial in Bladder Cancer
August 2008
18/08/08
Bioniche Phase III Clinical Trial in Bladder Cancer Progressing Well
May 2008
13/05/08
Bioniche Updates re: Mycobacterial Cell Wall Technology Platform
March 2008
04/03/08
Bioniche Receives Fast track Designation for First-Line Bladder Cancer Therapy
February 2008
13/02/08
Bioniche Provides Update on Refractory Bladder Cancer Trial with Urocidin™
August 2007
16/08/07
Bioniche Provides Update on Refractory Bladder Cancer Trial
May 2007
22/05/07
Data Shows Bioniche Proprietary MCC Technology Effective in Inducing Anticancer Activity in 3 Hours
April 2007
16/04/07
Bioniche Presents Additional Data on the Anticancer Activity of MCC Against Peritoneal Carcinomatosis
November 2006
08/11/06
First Patient Treated in Bioniche Phase III Refractory Bladder Cancer Trial
02/11/06
Bioniche Expands Patent Portfolio with Three New Patents
June 2006
29/06/06
Bioniche Presents Additional Data on Anticancer Activity of Mycobacterial Cell Wall-DNA Complex (MCC) Against Human Bladder Cancer Cells
May 2006
24/05/06
Mycobacterial Cell Wall-DNA Complex (MCC) Demonstrates Anticancer Activity in an Animal Model of Colon Cancer
23/05/06
Bioniche Closes Sale of its Proprietary Cystitis Product
04/05/06
U.S. FDA Grants Fast Track Designation for Bioniche Bladder Cancer Product
April 2006
03/04/06
Bioniche Receives FDA Approval to Proceed with Phase III Bladder Cancer Trials
March 2006
27/03/06
Bioniche to Host Bladder Cancer Roundtable
13/03/06
Bioniche Granted First Major Composition Patent for Oligonucleotide Technology
February 2006
07/02/06
U.S. FDA Accepts Part One of Bioniche Program for Phase III Clinical Trials with MCC for Bladder Cancer
July 2005
14/07/05
Bioniche Launches Sotradecol® Injection for Varicose Veins in U.S. Market
June 2005
17/06/05
Bioniche Issues Recall of BetacTM
16/06/05
Bioniche Presents Data on Anticancer Activity of Mycobacterial Cell Wall-DNA Complex (MCC) Against Peritoneal (Colon) Cancer
03/06/05
New Studies Demonstrate Immunomodulatory Activity of Bioniche Technology in Dogs
May 2005
26/05/05
Bioniche Granted European Patent for Mycobacterial Cell Wall-DNA Complex (MCC) as Prostate Cancer Treatment
April 2005
18/04/05
Bioniche Presents Data on Prevention and Management of Urinary Tract Infections Using Cystistat®
November 2004
22/11/04
FDA Approves Bioniche Pharma ANDA for Sotradecol Injection for the Treatment of Varicose Veins
09/11/04
Bioniche Discusses Further Details of the Phase III Clinical Trial with Urocidin for the Treatment of Bladder Cancer
July 2004
22/07/04
Bioniche Presents Pre-Clinical Data on Anti-Cancer Agents and Immunomodulatory Molecules at International Congress of Immunology
June 2004
14/06/04
Pharmacoeconomic Study into Use of Suplasyn® Demonstrates Reduced Pain and Cost-Effectiveness in Treatment of Patients with Osteoarthritis of the Knee
May 2004
20/05/04
Bioniche Presents Bladder Cancer Clinical Trial and Research Data to American Urological Association Annual Meeting
March 2004
29/03/04
Bioniche Announces Results of Phase I Prostate Cancer Study
|
